retatrutide phase 2 trial results Today, we shared new data from two 3 trials of retatrutide, our investigational triple agonist. Learn more: https://go.lilly.com/msrz1v Retatrutide yields results similar to

This is not about restriction but about giving your body a different pattern

While semaglutide and tirzepatide focus primarily on GLP-1 and GIP pathways, this peptide also activates the glucagon receptor, which boosts energy expenditure and weight reduction

Eat 3-5 prunes on days when bowel function seems sluggish

While Retatrutide reduces overall body fat effectively, some users find visceral deposits particularly stubborn

doi: 10.3389/fnut.2022.855223 Received 14 January 2022 Accepted 14 March 2022 Published 07 April 2022 Volume 9 - 2022 Edited by Christina Boyle, University of Zurich, Switzerland Reviewed by Micaela Morettini, Marche Polytechnic University, Italy